Nightingale Health OyjOMXHEX: HEALTH

HEALTH: Strong H2 revenue growth expected, driven by robust pipeline and expanded global partnerships

· Issued by Nightingale Health Oyj

Revenue grew 4% in H1, with strong order book and pilots supporting a reiterated 50% full-year growth target. Major partnerships expanded, new contracts secured, and US market entry advanced with the New York lab permit. H2 focus is on targeted sales and commercial scaling.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Nightingale Health Oyj on 6ix

Earlier from Nightingale Health

Later from Nightingale Health

All Nightingale Health news releases